Analyst Ratings For Tarsus Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analyst ratings for Tarsus Pharmaceuticals (NASDAQ:TARS) have shown a positive shift with an average 12-month price target of $50.17, up 18.97% from the previous target. Ratings have evolved over the past three months, with recent updates from analysts at Oppenheimer, Jefferies, Goldman Sachs, HC Wainwright & Co., and Barclays, all raising their price targets. Tarsus Pharmaceuticals, a commercial-stage biopharmaceutical company, has seen a revenue growth rate of 30.76% as of December 31, 2023, but struggles with a net margin of -320.45% and below-average ROE and ROA.
May 09, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals has received positive analyst ratings with raised price targets, indicating a bullish outlook. The company's significant revenue growth contrasts with its profitability challenges.
The positive shift in analyst ratings and raised price targets for TARS reflect growing confidence in the company's prospects, likely due to its substantial revenue growth. However, the company's struggles with profitability, as indicated by its negative net margin and below-average ROE and ROA, present challenges. The bullish outlook from analysts, combined with the company's operational achievements and challenges, suggests a nuanced but overall positive short-term impact on TARS's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100